Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors

Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, Ma H, Schubert P, Schweizer C, Fietkau R, Deutsch E, Gaipl U, Hecht M (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S1360-S1360

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2020.10.296

Authors with CRIS profile

Jianguo Zhou Department of Radiation Oncology Anna-Jasmina Donaubauer Department of Radiation Oncology Benjamin Frey Department of Radiation Oncology Ina Becker Department of Radiation Oncology Sandra Rutzner Department of Radiation Oncology Markus Eckstein Institute of Pathology Philipp Schubert Medizinische Fakultät Rainer Fietkau Lehrstuhl für Strahlentherapie Udo Gaipl Department of Radiation Oncology Markus Hecht Department of Radiation Oncology

Involved external institutions

Institut Gustave-Roussy FR France (FR) Zunyi Medical University CN China (CN)

How to cite

APA:

Zhou, J., Donaubauer, A.-J., Frey, B., Becker, I., Rutzner, S., Eckstein, M.,... Hecht, M. (2020). Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors. In ANNALS OF ONCOLOGY (pp. S1360-S1360). AMSTERDAM: ELSEVIER.

MLA:

Zhou, Jianguo, et al. "Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors." Proceedings of the ESMO Asia Virtual Congress AMSTERDAM: ELSEVIER, 2020. S1360-S1360.

BibTeX: Download